OncoScint (Cytogen Corp, Lonza Biologics)

OncoScint (Cytogen Corp, Lonza Biologics) - General Information

Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors.

 

Pharmacology of OncoScint (Cytogen Corp, Lonza Biologics)

Binds to the tumor associated glycoprotein 72 antigen, which is a cell surface protein generally over-expressed in colorectal cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of TAG-72 expressing cells and tumors

 

Additional information about OncoScint (Cytogen Corp, Lonza Biologics)

OncoScint (Cytogen Corp, Lonza Biologics) Indication: For diagnosis of extrahepatic malignant cancers
Mechanism Of Action: Binds selectively to cell-surface TAG-72 expressed on colorectal tumors.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Satumomab Pendetide
Synonyms: Not Available
Drug Category: Imaging Agents
Drug Type: Biotech; Approved

Other Brand Names containing Satumomab Pendetide: OncoScint (Cytogen Corp, Lonza Biologics);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production
Half Life: 0.8 hours (mammalian reticulocytes, in vitro)
Dosage Forms of OncoScint (Cytogen Corp, Lonza Biologics): Not Available
Chemical IUPAC Name: Murine anti-TAG72 antibody conjugated with Indium 111
Chemical Formula: C6268H9708N1666O1971S48
Satumomab Pendetide on Wikipedia: Not Available
Organisms Affected: Humans and other mammals